Inscinstech Files for IPO Following Nearly RMB 150 Million Raised in Three Consecutive Funding Rounds

Over the past year,Inscinstech Has Successfully Completed Its Series A+, B, and B+ Financing Rounds, with Total Transaction Amounts Approaching RMB 150 Million. The Three Rounds Were Led by Singapore’s ESCO, Luxin Venture Capital, and Qiming Venture Partners, Respectively; Qianhai Infrastructure and Wuxi Financial Holdings Zhiyuan Participated as Co-investors, While Existing Shareholders Yida Capital and Matrix Partners China Continued to Increase Their Investments.The financing proceeds will be allocated to the R&D of upstream CMC process tools for biopharmaceuticals, expansion of production capacity, and global market development. Life Capital has served as Inscinstech’s exclusive financial advisor across multiple consecutive funding rounds.

Inscinstech is an innovative high-tech enterprise specializing in CMC process tools for the biotechnology sector, dedicated to providing comprehensive solutions for CMC process development in biopharmaceuticals.Inscinstech has established three major R&D centers in Suzhou, Beijing, and Boston, USA, bringing together highly innovative and visionary technical talents. Its core technical team has previously engaged in the research and development of high-end scientific instruments, such as chromatography, spectroscopy, and mass spectrometry, at top-tier global scientific instrument companies. By mastering the core key technologies of liquid chromatography, spectroscopy, and mass spectrometry, Inscinstech has laid a solid foundation for the development of superior bioscience instruments and equipment.

Despite the slowdown in the overall growth of the biopharmaceutical sector in 2022 compared to the previous year, due to factors such as the pandemic, Inscinstech achieved a year-over-year revenue growth rate of over 100% by offering highly competitive, high-quality products and services. To date, Inscinstech has served more than 600 biopharmaceutical clients worldwide, contributing to the realization of “product value and service value,” “efficiency enhancement and cost reduction,” and “independent controllability” for its customers.

“Throughout 2022, the entire capital market was in a winter period, yet Inscinstech still bucked the trend and completed three rounds of financing, accumulating nearly 150 million RMB. We sincerely thank all investors for their recognition and support of Inscinstech. This financing will accelerate the R&D speed of Inscinstech's overall product line, increase production capacity, and expand into global markets, enabling us to provide higher-quality products and more efficient services to our global customers faster and better.”Li Dawei, founder of Inscinstech, stated“We will continue to adhere to a market-oriented approach and be driven by technological innovation, providing global biopharmaceutical customers with more advanced life science instruments and equipment, contributing to the realization of self-reliance and controllability, and creating value for our customers.”

In recent years, Inscinstech has successively launched a series of products in the fields of cell and gene therapy (CGT), antibody-drug conjugates (ADCs), nucleic acid drugs, and mRNA vaccines, including protein purification systems, large-scale nucleic acid synthesizers, and nano-drug assembly systems. Its product portfolio covers laboratory-scale and pilot-scale equipment, and has rapidly gained recognition and favor from customers both domestically and internationally since its market launch. Looking ahead, Inscinstech will continue to focus on the biotechnology sector, striving to become a comprehensive solution provider encompassing upstream and downstream processing, formulation, and laboratory analytical testing.

Inscinstech Product Line

Lin Xiangqian, Chairman and CEO of Esco Biosciencesstated: “As the most critical technological platforms in the process chains of emerging fields such as biopharmaceuticals and Cell and Gene Therapy (CGT), protein purification, nucleic acid synthesis, and nanomedicine preparation are vital to final product quality, production efficiency, and cost control. From laboratory research and pilot-scale scale-up to commercial-scale manufacturing, large-scale, high-quality domestically produced protein purification systems and fully automated synthesis and preparation systems represent the prevailing trend in industry development. Yishike Bio is honored to participate in Inscinstech’s Series A+ financing round. This decision reflects our confidence in their professional, solid team with a mature industrial perspective, which boasts over a decade of industry experience in sample pretreatment, chromatography, spectroscopy, and automation. Within just a few years, Inscinstech has positioned itself at the forefront of leading the independent R&D and commercialization of high-end domestic instruments and equipment. By launching innovative purification, synthesis, and preparation systems with fully independent intellectual property rights, it has broken through the technical barriers and industrial monopolies established by international brands in the application market. We also look forward to leveraging Yishike Bio’s international platform advantages to help Inscinstech become a leading comprehensive solution provider in fields such as protein purification and nucleic acid synthesis, thereby adding global growth momentum for business partners who share our aspirations.”

Du Lin, Partner at Huaxin Capital, a subsidiary of Luxin Venture Capitalstated: “The life sciences and biopharmaceutical industries are developing rapidly, accompanied by the severe challenge of global biopharmaceutical supply chain instability. We focus on localization opportunities in the upstream segment of the biopharmaceutical industry and seek out outstanding domestic suppliers with independent intellectual property rights and core component development capabilities. Inscinstech is such an exemplary enterprise. Inscinstech possesses a proprietary liquid chromatography underlying technology platform, based on which it has developed protein purification systems, nucleic acid synthesis systems, and nanodrug assembly systems. The company demonstrates strong product development capabilities and can effectively and rapidly bring products to market. Its team is pragmatic and highly executable. As the lead investor in Series B financing, we will support Inscinstech in continuously enriching its product portfolio, expanding its global channels, and providing excellent upstream solutions to biopharmaceutical enterprises both domestically and internationally.”

Zhang Ao, Executive Director of Qiming Venture Partners“The Inscinstech team has extensive experience in R&D and industrialization within the field of biopharmaceutical instruments and equipment. In particular, its laboratory protein purification systems have gained widespread customer recognition, and the company is gradually extending this product series to pilot-scale and manufacturing stages. Meanwhile, keeping pace with industry developments and customer needs, the company has rapidly launched core products in areas such as ultrafiltration, nucleic acid synthesis, and gene therapy, while progressively expanding into overseas markets. We greatly admire the Inscinstech team’s innovation capability through independent R&D, strong execution, and resource integration capabilities. We are optimistic about the company and believe it will develop into a well-known brand in the field of core biopharmaceutical instruments and equipment.”

Li Shengwen, Managing Director of Life Capital“The Inscinstech team’s close collaboration throughout the financing process is greatly appreciated, and it has been a distinct honor to support Inscinstech through multiple rounds of financing. As a leading enterprise in China’s life science instrumentation sector, Inscinstech is one of the few companies with independent R&D and manufacturing capabilities for core critical components. By starting with proprietary core components at the most fundamental level, the company has developed a comprehensive suite of instruments covering nucleic acid synthesis, ultrafiltration, purification, nanomedicine preparation, and analytical testing. Leveraging the founding team’s extensive industry experience, the company has meticulously crafted its products from laboratory-scale to pilot-scale and full production-scale, establishing a leading end-to-end life science instrumentation platform in China’s cell and gene therapy (CGT) field. Its high-quality products have secured strategic partnerships with numerous biopharmaceutical companies both domestically and internationally.”